Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 November 2020 | Story Dr Nitha Ramnath | Photo Supplied
The UFS team, from the left: Monique Harcourt, Dawid Potgieter, Atalanta Watson, and Zoe Travers.

One of two teams from the University of the Free State (UFS) performed exceptionally well and made it to the top four in the extremely competitive local Chartered Financial Analyst (CFA) University Challenge.

The CFA Society South Africa recently hosted the 12th annual local edition of the CFA Institute University Research Challenge. The research challenge is an annual global competition in equity research hosted by the CFA Institute, a global representative body for chartered financial analyst (CFA) charter holders. During the research challenge, teams from different universities locally and internationally compete on three levels – more than 1 000 universities compete annually.  

"Taking part in the CFA challenge was a wonderful opportunity where we learnt new skills and gained industry-specific experience, which will be invaluable to us as we graduate and embark on our journey as professionals. We are proud to have represented Kovsies in the finals and this proved to us, once again, that hard work pays off, " said the UFS team.

Two teams of four were selected to represent the UFS during the 2020 challenge. Team selection was based on students’ performance during the first semester of their BCom Honours (specialisation in Financial Economics and Investment Management) in the Department of Economics and Finance. During the challenge, students assumed the role of a (sell-side) research analyst and had to write a concise report that covered various aspects related to the company’s business activities, structure, governance, finances, etc., which was presented via Zoom to a panel of judges from the CFA Society South Africa. 

Dr Ivan van der Merwe, the team’s adviser from the Department of Economics and Finance, commented: “It was a pleasure to work with a team that showed so much dedication and was willing to go the extra mile. The experience they gained during this challenge will stand them in good stead and it was a real confidence builder for them to successfully complete a very stressful live presentation and subsequent question session. They made us proud and set the standard for aspiring Finance students at Kovsies.” 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept